Canonical: https://ownershiptrace.com/13f/companies/2084

# Who owns Cellectar Biosciences, Inc. (CLR)? Elite investor 13F holders

1 tracked elite investors reported holding Cellectar Biosciences, Inc as of 2026-06-30, including Caligan Partners. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

1 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with…

## Reported holders and securities, including exits (up to 20)

| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|  --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [Caligan Partners](https://ownershiptrace.com/13f/investors/125) | CELLECTAR BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1306594.00 USD | 469998.000000 | Shares | buy | [Original filing](https://www.sec.gov/Archives/edgar/data/1727492/0001420506-26-001809-index.html) |

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

[How to read the data](https://ownershiptrace.com/docs#reading-the-data) · [Disclaimer](https://ownershiptrace.com/disclaimer)